Connect with us

Press Releases

EssilorLuxottica Unveils Four-Year Clinical Trial Results of Its Essilor Stellest Lens at the 2023 Annual Meeting of the ARVO

Latest findings released for the first time show sustained myopia control efficacy of the lens in children, saving more than one and a quarter dioptres of myopia over four years.




(PRESS RELEASE) CHARENTON-LE-PONT, FRANCE — EssilorLuxottica presented the four-year clinical trial results of its myopia control innovation Essilor Stellest lens for the first time at the 2023 ARVO annual meeting in New Orleans United States. The findings show that Essilor Stellest lenses continue to exhibit strong efficacy in slowing myopia progression and axial eye elongation in children in the fourth year.

The clinical trial which began in 2018 was conducted at the Eye Hospital of Wenzhou Medical University in Wenzhou, China. The study assessed the four-year increase of myopia and axial eye length of children who wore spectacle lenses with highly aspherical lenslets (HAL). Essilor Stellest lenses are based on the optical design of HAL lenses. The key findings from the study include:

  • HAL lenses saved more than one and a quarter dioptres of myopia on average over four years, demonstrating conclusive evidence of their effectiveness in slowing down myopia progression in children in the fourth year.
  • Myopia progression and axial eye elongation in children wearing HAL lenses was slower compared to a modeled control single vision lens group1, again indicating sustained myopia control efficacy of the lenses in the fourth year.
  • HAL lenses remain effective in slowing myopia progression and axial eye elongation in older children (11-16 y.o.) in the fourth year.

The four-year results were presented by Dr. Björn Drobe from EssilorLuxottica’s R&D team. Dr. Yee Ling Wong from the R&D team presented findings from a study that evaluated the eye growth of children wearing spectacle lenses with aspherical lenslets and with single-vision lenses in comparison to eye growth patterns in non-myopic children in Wenzhou, China. These findings concluded that the eye growth pattern in 9 out of 10 children wearing HAL lenses full-time was similar or slower than that of non-myopic children, after two years.

The release of the four-year data follows the recent publication of the three-year clinical trial findings in the medical journal American Journal of Ophthalmology, which also highlights evidence of continued myopia control efficacy of the lens in slowing down myopia progression in children over three years. When children switched to HAL lenses in the third year after two years of wearing single vision lenses, myopia progression and axial eye elongation decreased significantly, compared to children wearing single vision lenses. The link to the article can be found here.

Norbert Gorny, co-chief operating officer at EssilorLuxottica, said, “We are proud to share the latest findings from our four-year study of the Essilor Stellest lens at ARVO, which demonstrate that the myopia control effect of the lens is sustainable over four years. We look forward to sharing additional data with the scientific community. Such encouraging, evidence-based findings will significantly help to enhance scientific understanding and clinical interest for myopia control solutions like the Essilor Stellest lens globally. To move the needle further, we will continue to advance myopia research, deliver innovative solutions, build partnerships to strengthen awareness and education, share insights and expertise at key conferences, and much more.”




The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular